Lisa Ricciardi bought $10k of CGTX
CEO & President at COGNITION THERAPEUTICS INC. 9,175 shares at an average of $1.10, traded Apr 16, 2026, filed Apr 20, 2026.
Score components
- +25RoleCEO
- 0Trade size$10k at market
- -5Relative to holdingsUnder 1% of holdings (0.5%)
- +8Price context65% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +15.2%, 3m -15.3%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-045502, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 16, 2026 | POpen-market purchase Common Stock | +9,175 | $1.10 | $10k | 1,715,851 | Apr 20, 2026 |
Related signals
Other insiders at COGNITION THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | COGNITION THERAPEUTICS INC | Anthony Caggiano Chief Medical Officer | $11k 10,000 shares | +1% | |
| 45Moderate | COGNITION THERAPEUTICS INC | John Brendan Doyle Chief Financial Officer | $11k 10,000 shares | +2% | |
| 38Weak | CGTXbuy COGNITION THERAPEUTICS INC | Lisa Ricciardi CEO & President | $30k 38,851 shares | - | |
| 33Weak | CGTXbuy COGNITION THERAPEUTICS INC | Lisa Ricciardi CEO & President | $9,975 5,700 shares | +2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.